Glioblastoma Multiforme
Conditions
Keywords
FET-PET, Glioblastoma, GBM, 0-(2-18F-Fluoroethyl)-L-Tyrosine (FET), Glioma
Brief summary
Glioblastoma multiforme (GBM) represent the most common primary brain malignancy and prognosis remains poor. The most common subtype is glioblastoma which has a 5-year survival rate of approximately 5%. Despite advances in MRI techniques, accurately determining total extent of tumor remains a challenge. The result is incomplete treatment resulting in reduced survival or overtreatment resulting in avoidable treatment related morbidity. A more accurate means of assessing tumor extent is needed to guide management to improve patient survival and quality of life.
Interventions
DIAGNOSTIC_TESTFET-PET/MRI
Radiation planning target volume (PTV) when planned with FET-PET/MRI to PTV when planned with conventional (Standard of Care) MRI only. 0-(2-18F-Fluoroethyl)-L-Tyrosine (FET) 180-200 megabecquerel (MBq) administered intravenously prior to PET/MRI imaging.
Sponsors
Sunnybrook Health Sciences Centre
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Each participant must meet all of the following inclusion criteria to participate in this study: * ≥ 18 years of age * Diagnosis of glioblastoma multiforme * Post-maximally safe surgical resection * No prior radiation or systemic treatment for high grade glioma * Able to tolerate PET/MRI scan with intravenous contrast * Willing to provide informed consent
Exclusion criteria
All participants meeting any of the following
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Difference in radiation treatment volume as determined by FET-PET/MRI compared to standard of care MRI. | 12 months | Volume difference measured in cubic centimetres |
Other
| Measure | Time frame | Description |
|---|---|---|
| Difference in pre- and post-treatment metabolic tumor volume as determined by FET-PET. | 12 months | Volume difference measured in cubic centimetres |
| Overall and recurrence-free survival post radiation treatment. | 12 months | Measured in months |
| Quality of life changes pre and post radiation treatment. | 12 months | Units on a scale - Linear Analog Self-Assessment, score minimum = 0, score maximum = 10, higher is better |
Countries
Canada
Outcome results
None listed